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Abstract
Hemodynamic instability is a common problem in neonates and has important implications for long-term outcomes. Inotropes and vasopressors are commonly used to treat low blood pressure or poor perfusion in neonatal intensive care, despite limited evidence to guide optimal management in specific clinical situations. Dopamine is the most commonly used agent in clinical practice, increasing blood pressure with limited adverse effects compared with epinephrine. Dobutamine is less commonly used but may be the optimal agent for premature neonates with poor perfusion due to immature myocardial contractility. New evidence is emerging to guide the treatment of hypotension in the setting of sepsis and persistent pulmonary hypertension. Norepinephrine and vasopressin may have utility in the setting of refractory hypotension due to sepsis. Increasing evidence supports use of norepinephrine, milrinone, and vasopressin in the setting of persistent pulmonary hypertension. Hydrocortisone should be reserved for vasopressor-resistant hypotension in preterm neonates; however, this agent may also prove useful in the treatment of persistent pulmonary hypertension in term neonates. Further clinical trials are necessary to determine the optimal treatment algorithm for neonates with hemodynamic instability. Future trials should include physiologically relevant end points and long-term follow-up. However, one approach may not be efficacious for all neonates even with a similar diagnosis. Therefore, bedside assessment techniques should continue to be explored to allow tailored therapy based on real-time assessment of underlying physiology.
Introduction
Hemodynamic instability represents an ongoing challenge in the management of critically ill neonates. (1) Neonatal hypotension has been associated with brain injury, (2) necrotizing enterocolitis, (2) retinopathy of prematurity, (2) and death. (1) Unfortunately, recognition (2)(3) and management of hypotension in the neonate can be exceedingly difficult (4)(5) partly because normative blood pressure parameters are not standardized in neonates and hypotension alone does not predict negative outcomes. (6) There are multiple accepted definitions of hypotension in neonates; however having hypotension does not necessarily equal inadequate end-organ perfusion. (7) Recently, the focus of clinicians and researchers has shifted from blood pressure to end-organ perfusion. (8) For the purpose of this article, the term hypotension is used to reflect an inadequate blood pressure to maintain end-organ perfusion. Importantly, poor cerebral perfusion has been associated with brain injury, death, and neurodevelopmental impairment in early childhood. (9) There are emerging technologies, such as functional echocardiography and near-infrared spectroscopy, that allow real-time assessment of cardiac output and cerebral blood flow. (10) In addition to a change in evaluation strategies, the appropriate goals of cardiovascular support in neonates have also been questioned. Historically, trials of medications for the treatment of hemodynamic instability in neonates focused primarily on the correction of hypotension. However, attention is increasingly directed toward assessment of perfusion and the effect of various interventions on long-term outcomes. (5) The aims of this article are to review the inotropes most commonly used in neonatology, discuss other pharmacologic management strategies for hypotension and hypoperfusion in neonates, and discuss clinical factors that affect medication selection.
Catecholamines Dopamine
Dopamine is an endogenous sympathomimetic amine that potentiates the release of norepinephrine in addition to direct action on a-, b-, and dopaminergic receptors. (1)(4) (11)(12) a 1 -receptor stimulation produces systemic vasoconstriction, and b 1 -receptor stimulation increases cardiac output through positive inotropy (ie, myocardial contractility) and chronotropy (ie, heart rate). Dopaminergic receptor stimulation increases renal blood flow through renal vasodilation, change in tubular absorption, and positive inotropy. (6) Stimulation of dopaminergic receptors is also responsible for the endocrine effects of dopamine, including decreased thyrotropin, prolactin, and thyroxine. (13) Potential negative effects of dopamine include abnormalities of the endocrine system, arrhythmias, and an increase in pulmonary vascular resistance. (11) (12) The receptor effects of dopamine are dose dependent in children and adults, with a low dose (0.5-2 mg/kg/min) acting on dopaminergic receptors, a medium dose (2-6 mg/kg/min) acting on cardiac b 1 -receptors, and a higher dose of greater than 6-10 mg/kg/min acting on a 1 -receptors (Table 1) . (11) However, the effective dose to stimulate each receptor subtype varies substantially among neonates. Premature neonates may be affected by dopamine at lower doses secondary to decreased metabolism of the drug. (6) Conversely, premature neonates may be relatively resistant to dopamine secondary to blunted norepinephrine release as a result of immature sympathetic innervation. Dopamine is the most commonly used drug for the management of hypotension by neonatologists. (4)(14) It is more effective at increasing mean arterial pressure (MAP) than dobutamine. (15)(16) When compared with epinephrine for treatment of hypotension in low-birthweight neonates, it has a comparable effect on MAP and urine output. (17) Although the use of epinephrine is associated with a higher incidence of transitory metabolic effects, such as hyperglycemia, increased plasma lactate level, and lower bicarbonate level, there is no difference in the incidence of gastrointestinal complications and mortality. (14)(17) Dopamine also increases peripheral perfusion in normotensive very low-birth-weight (VLBW) neonates (18) and increases cerebral blood flow and tissue oxygenation in hypotensive VLBW neonates. (14) It is plausible that the abrupt increases in MAP found in these trials may place VLBW neonates at risk for brain injury. Further research is needed to evaluate the effect of dopamine on brain injury and long-term neurodevelopmental outcomes.
Dopamine is also the most commonly used therapy for treatment of hypotension associated with persistent pulmonary hypertension of the newborn (PPHN). Although dopamine is highly effective at increasing MAP in these patients, it may also increase pulmonary vascular resistance, compromising oxygenation. (3) Literature regarding the outcomes of neonates with PPHN treated with dopamine is lacking, and trials demonstrating its benefit are needed. Dobutamine significantly increases cardiac output but does not have a significant effect on endogenous catecholamine levels, MAP, or heart rate in preterm neonates. (19) Dobutamine increases renal perfusion, likely because of decreased systemic vascular resistance rather than a direct effect on the kidneys. (20) Although dopamine more effectively increases blood pressure, dobutamine more effectively increases systemic blood flow in preterm neonates. (15) A comparative trial of dobutamine vs dopamine in preterm neonates with low cerebral blood flow found no difference in mortality but a reduction in late grade III or IV intraventricular hemorrhage. (23) The follow-up for this trial revealed that neonates treated with dobutamine incurred significantly less disability (eg, cerebral palsy, blindness, deafness, and severe developmental delay) in early childhood. (9) However, the trial found no difference in the overall incidence of intraventricular hemorrhage or the combined rates of death or disability at 3 years of age. There was a significant crossover between the treatment groups and a high rate of treatment failure despite crossover, which limits the possible conclusions from this trial. Further studies are necessary to define the outcomes of preterm neonates treated with dobutamine. Dobutamine has also been described for the treatment of myocardial dysfunction secondary to PPHN. In animal models, dobutamine improves myocardial function, decreases pulmonary vascular resistance, and improves oxygen delivery. (4) However, dobutamine has not been formally studied for this indication in clinical trials in human neonates and needs further investigation before routine use.
Epinephrine
Epinephrine is an endogenous catecholamine that stimulates a 1,2 -and b 1,2 -receptors. (3)(12) The b-receptor effect is seen at low doses (0.01-0.1 mg/kg/min) and causes an increase in myocardial contractility with associated peripheral vasodilation. (12)(14) High-dose epinephrine (>0.1 mg/kg/min) is associated with increased systemic vascular resistance due to a-receptor-mediated peripheral vasoconstriction (Table 1) . (3)(22) Notably, dose thresholds have not been established in neonates. The possible negative effects of epinephrine include tachycardia, arrhythmias, peripheral ischemia, lactic acidosis, and hyperglycemia. (17) (21) Importantly, tachycardia is most likely attributable to b 2 -receptor stimulation in the heart, while lactic acidosis and hyperglycemia are most likely attributable to b 2 -receptor stimulation in the liver. Excessive vasoconstriction leading to peripheral ischemia occurs predominantly at high doses and does not represent the most likely cause of these adverse effects in routine clinical practice.
Epinephrine is primarily used in neonates with hypotension refractory to first-line therapies. As primary therapy, epinephrine increases blood pressure with an efficacy similar to dopamine, although producing increases in heart rate, plasma lactate level, and blood glucose level. (17) Importantly, these adverse effects do not appear to produce a difference in short-term clinical outcomes between therapies. (22) Similar effects occur when epinephrine is used to treat hypotension unresponsive to dopamine in VLBW infants. In this setting, improvements in blood pressure occur in the context of a worsening base deficit. (24) Of interest, epinephrine increases cerebral blood flow in extremely preterm neonates, potentially to a greater degree than dopamine. (14) As with dopamine, the effect of epinephrine on brain injury and subsequent outcome has not been adequately described. Epinephrine has also been evaluated for the treatment of systemic hypotension associated with PPHN in preclinical models. (25) In this setting, epinephrine produces similar increases in cardiac output to dopamine; however, epinephrine increases systemic vascular resistance preferentially over pulmonary vascular resistance. (25) These findings are most likely secondary to a 2 -mediated nitric oxide production, resulting in relative pulmonary vasodilation. (26)(27) However, the role of epinephrine in human neonates with PPHN has not been evaluated. The utility of epinephrine is likely limited by the occurrence of tachycardia and lactic acidosis, which may negatively affect the pathophysiology of PPHN. Until further studies are performed evaluating long-term outcomes, it is difficult to recommend epinephrine over other inotropes for treatment of PPHN.
Norepinephrine
Norepinephrine is an endogenous catecholamine that increases systemic vascular resistance and cardiac output by activation of a 1,2 -and b 1 -receptors (Table 1) . (22)(27) As with epinephrine, norepinephrine constricts systemic vasculature to a greater degree than pulmonary vasculature. (26)(27) Norepinephrine also increases cardiac output by increasing contractility via b 1 -receptors, although this effect is less pronounced in the setting of potent a-receptormediated vasoconstriction. The potential negative effects of norepinephrine include excessive peripheral vasoconstriction, leading to tissue ischemia. (6) Norepinephrine is widely used for the management of hypotension secondary to septic shock in adult and pediatric patients. In adult patients with septic shock, norepinephrine improves survival when compared with dopamine. (28) In 2012, the Surviving Sepsis Campaign's International Guidelines recommended norepinephrine as the first-line agent for treatment of adult patients and the second-line treatment of pediatric patients with hypotension secondary to septic shock. (29) At this time, dopamine remains the first agent for treatment of septic shock in pediatric patients. Although norepinephrine has become the standard of care for treatment of vasodilatory septic shock in adults and children, it is not commonly used in neonates. (7) Clinical experience in the setting of sepsis is limited to an observational report of term neonates with refractory hypotension, defined as persisting despite fluid resuscitation plus dopamine or dobutamine with or without hydrocortisone. In this setting, norepinephrine increases MAP, decreases oxygen requirement, and improves tissue perfusion. (1) A high rate of mortality (18%) makes the results of this observational study difficult to interpret given the acuity of illness before initiation of treatment with norepinephrine. Given the benefits of norepinephrine in pediatric and adult patients with septic shock, further investigation in neonates is warranted.
Norepinephrine has also been evaluated in neonates with PPHN. Preclinical data suggest that norepinephrine produces pulmonary vasodilation during fetal life via a 2 -receptor stimulation. (26) Although preclinical data are promising, published experience in human neonates is limited to observational reports. (26)(27) In term neonates with PPHN treated with inhaled nitric oxide, norepinephrine decreases oxygen requirement, increases cardiac output, and improves blood flow into the lungs, without evidence of peripheral ischemia. (30) Further investigation, potentially including trials comparing norepinephrine to current standards of care, appears warranted.
Adjuncts and Alternatives to Catecholamines Milrinone
Milrinone is a phosphodiesterase type 3 inhibitor with inotropic, inodilator (promotes myocardial contractility and produces vasodilation), and lusitropic (promotes myocardial relaxation) properties. (5)(31) (31) Milrinone has primarily been investigated in infants for the prevention and treatment of low cardiac output after cardiac surgery. (19) In this setting, milrinone decreases systemic and pulmonary vascular resistance while increasing cardiac index. Despite these physiologic benefits, milrinone does not appear to alter early postoperative outcomes. (36) Dose optimization studies that incorporate age, disease, and type of surgery as covariates are being undertaken in an effort to link milrinone's favorable hemodynamic profile to improved patient outcomes. (37) Theoretically, milrinone could be ideal to treat low cerebral blood flow commonly seen in conjunction with reduced myocardial contractility in extremely preterm neonates. (38) Unfortunately, a randomized clinical trial that used milrinone to ameliorate low cerebral blood flow in extremely preterm neonates did not find a benefit with regard to systemic blood flow, brain injury, or mortality. (34) The limitations of this trial included the low incidence of low cerebral blood flow in both the treatment and control groups, administration of a normal saline bolus to all neonates, and administration of prophylactic indomethacin to more than half of the enrolled neonates. Pending further investigation, milrinone cannot be recommended as the primary inotrope for preterm infants in the early neonatal period.
Milrinone has also been evaluated for the treatment of PPHN. Through phosphodiesterase inhibition, milrinone augments the pulmonary vasodilation induced by nitric oxide. (39) In observational clinical trials, milrinone decreases pulmonary artery pressures and oxygenation index without a significant effect on blood pressure. (33)(40) These findings are promising and require further investigation, including trials focusing on the effect of milrinone therapy on outcome in neonates with PPHN. However, in these trials, milrinone was used in the setting of PPHN unresponsive to inhaled nitric oxide and in neonates who were hemodynamically stable. Milrinone should be used with caution in PPHN with associated hypotension because of the potential for decreased coronary perfusion.
Milrinone has unique pharmacokinetic properties compared with the other inotropes discussed in this review. A relatively large volume of distribution necessitates that a loading dose be used before continuous infusion to achieve therapeutic concentrations in the acute care setting. There are age-related differences in clearance, but generally speaking, the half-life of milrinone is 1.5 to 3.5 hours compared with 1 to 2 minutes for the other inotropes. (41) Practically speaking, this means that the physiologic effects of milrinone persist long after the drug is weaned. In addition, administration of the loading dose can produce profound hypotension, leading many practitioners to forgo the loading dose in favor of a higher initial infusion rate and delayed drug onset.
Vasopressin
Endogenous arginine-vasopressin (AVP) is a neuropeptide that increases vascular tone and regulates fluid homeostasis by binding to vasopressin 1 (V1) and vasopressin 2 (V2) receptors in smooth muscle. (42) The selective pulmonary vasodilatory effects of lowdose AVP make this agent appealing for the treatment of PPHN. Benefits in neonates were first observed in the setting of severe pulmonary hypertension after repair of obstructive total anomalous pulmonary venous return. (47) Subsequently, a case series in neonates with PPHN found that low-dose AVP improved blood pressure, urine output, and oxygenation index while reducing the requirement for inhaled nitric oxide. (48) Adverse effects were not observed. The role of AVP as a primary systemic vasopressor and pulmonary vasodilator for the treatment of neonates with PPHN requires further evaluation.
Hydrocortisone
Hydrocortisone is inferior to dopamine as a first-line agent for the treatment of neonatal hypotension, with a delayed onset followed by significant hypertension after 24 to 48 hours of therapy. Relative or absolute adrenal insufficiency may be present in neonates with refractory hypotension secondary to decreased cortisol stores and decreased ability to increase cortisol in response to stress. (49) Diagnosing adrenal insufficiency in neonates is challenging, with normal cortisol levels varying with gestational age, weight, and severity of illness. Importantly, a normal cortisol level in the setting of stress may indicate relative adrenal insufficiency in a neonate that will respond to hydrocortisone supplementation. Corticosteroids aid in the management of hypotension by decreasing the breakdown of catecholamines, increasing calcium levels in myocardial cells, and upregulating adrenergic receptors. (6) Adverse effects of corticosteroids include hyperglycemia, gastric irritation, and fluid retention. Long-term exposure increases the risk of osteopenia and inhibits immune function and somatic growth.
The optimal timing of hydrocortisone therapy for the prevention and treatment of hypotension in preterm neonates has been extensively explored. Hydrocortisone prophylaxis in preterm neonates has been suggested to prevent adrenal insufficiency and subsequent complications of uninhibited inflammation. (2) In a randomized clinical trial, neonates exposed to histologic chorioamnionitis had lower mortality when treated with prophylactic hydrocortisone soon after birth. Importantly, this trial was halted early because of the high incidence of spontaneous intestinal perforations in the treatment group. Subsequent analysis revealed that this complication occurred predominantly in the setting of concurrent indomethacin therapy. (50) As discussed previously, hydrocortisone is inferior to dopamine as a first-line agent for the treatment of neonatal hypotension. (16) Multiple studies have evaluated hydrocortisone in preterm neonates with refractory hypotension. Hydrocortisone effectively increases blood pressure and reduces catecholamine requirement without serious adverse events. (49) The long-term effect of hydrocortisone as an adjunctive therapy in the setting of catecholamine-resistant hypotension has not been evaluated. Whether improvements in blood pressure and reduction in pharmacology / inotrope and vasopressor support catecholamine use are associated with improved survival and neurodevelopmental outcome remains to be seen.
Hydrocortisone has been less extensively evaluated for the treatment of PPHN in term neonates. In neonatal lambs, hydrocortisone treatment at clinically relevant doses improves oxygenation and decreases hyperoxiainduced changes in soluble guanylate cyclase and phosphodiesterase type 5 activity, increasing cyclic guanosine monophosphate levels. (51) Additional potential benefits include reduced ventilation-perfusion mismatch due to decreased pulmonary inflammation and reduced right-to-left patent ductus arteriosus shunting due to increased systemic blood pressure. It remains to be determined whether these physiologic benefits will be verified in human neonates and whether these effects improve clinical outcomes.
Conclusion
Current standard of care dictates the use of dopamine as the first-line agent for the management of hypotension and hypoperfusion in the neonate regardless of the clinical scenario (ie, transition period, sepsis, or PPHN). This is primarily based on historical data and the comfort level of clinicians. However, there is emerging evidence that challenges the routine use of dopamine as the first-line therapy in every clinical situation. Data support the use of dobutamine during the transition period, epinephrine for sepsis, norepinephrine and vasopressin for sepsis and/or PPHN, and milrinone for PPHN. Although dopamine has proven to be an effective drug at increasing MAP, it has not been found to improve long-term outcomes in neonates. Randomized clinical trials are needed to evaluate the use of dopamine and other inotropes and vasopressors in specific clinical situations, such as sepsis and PPHN. Careful analysis of data from smaller clinical trials evaluating the efficacy and safety of the available agents in neonates must guide construction of these trials. In addition, future trials should focus on defining and measuring physiologically relevant end points, such as systemic and cerebral oxygen delivery, and on tailoring drug selection and dose titration to the underlying pathophysiologic findings of the neonate.
5.
A 28-week gestational age male infant is now 10 days old and has hypotension associated with a new-onset infection. The team considers the use of hydrocortisone for his condition. Which of the following statements regarding hydrocortisone for the treatment of neonatal hypotension is correct? A. If there is a normal age-specific cortisol level obtained, there is no indication of absolute or relative adrenal insufficiency; therefore, corticosteroids will have no effect. B. A potential side benefit of hydrocortisone therapy is increased growth and improved bone maturation. C. Corticosteroids address hypotension by acting on calcium channel receptors in smooth muscle, leading to decreased calcium levels in myocardial and endothelial cells. D. Prophylactic hydrocortisone and concurrent indomethacin therapy has been associated with spontaneous intestinal perforation. E. Low-dose hydrocortisone given prophylactically or in the setting of hypotension leads to improved survival and neurodevelopmental outcomes.
